India Pharma Outlook Team | Friday, 18 September 2026
AstraZeneca’s England approval signals wider access to cancer care and marks a clear advance for patients.
NICE clears Enhertu for use on the National Health Service in England after earlier cost-effectiveness concerns blocked funding.
AstraZeneca and Daiichi Sankyo now open the door for roughly 1,000 women each year who live with HER2-low metastatic breast cancer.
The drug already reaches patients in Scotland since 2023, and the companies plan to seek the same access in Wales and Northern Ireland.
This decision turns a targeted therapy into a practical treatment option inside England’s public system. It also reflects recent shifts in how Britain values late-stage cancer medicines and prices innovative drugs. Wider access now moves from policy discussion into everyday clinical reality for eligible patients.
Enhertu works by delivering chemotherapy directly to tumors that express the HER2 protein while it spares healthy cells. Doctors can prescribe the medicine for HER2-low metastatic breast cancer, a form that previously offered fewer targeted options.
AstraZeneca and Daiichi Sankyo confirm that about 1,000 women a year in England become eligible under the new recommendation. The companies keep the commercial terms of the NICE agreement confidential, yet the list price stands at £1,455 per 100 mg vial.
Also Read: Why Peptides and Complex Generics Will Define India Pharma's Future
NICE previously rejected funding for Enhertu on cost-effectiveness grounds. Recent changes to Britain’s evaluation methods for late-stage cancer medicines remove that barrier. A broader US-UK agreement also aims to bring British drug prices closer to American levels over time.
Laura McMullin, UK general manager at Daiichi Sankyo, calls the revised approach “a positive initial step” that enables the current outcome. The companies now prepare applications for health bodies in Wales and Northern Ireland so that access can expand across the United Kingdom.
Trial evidence from 2022 shows Enhertu extends survival for some patients by roughly six months. Regulators in several countries already approve the medicine for certain breast, gastric and lung cancers.
England’s decision therefore aligns the country’s largest health service with international practice. For patients and clinicians, the approval means a proven option moves from limited availability into routine NHS pathways. For the industry, the outcome demonstrates that adjusted valuation methods can unlock access without abandoning rigorous assessment.
AstraZeneca and Daiichi Sankyo will pursue formal approvals in Wales and Northern Ireland. Successful decisions there would create consistent availability of Enhertu across all four UK nations.
In the meantime, eligible patients in England gain immediate access through the NHS. The companies and health authorities now shift focus from negotiation to delivery so that the survival benefit reaches those who need it most.
AstraZeneca’s England approval therefore does more than add one medicine to the formulary. It signals that wider access to cancer care remains achievable when clinical evidence, pricing dialogue and policy reform move forward together.
.jpg)
